Back to Search Start Over

Development of a Series of Pyrrolopyridone MAT2A Inhibitors.

Authors :
Atkinson SJ
Bagal SK
Argyrou A
Askin S
Cheung T
Chiarparin E
Coen M
Collie IT
Dale IL
De Fusco C
Dillman K
Evans L
Feron LJ
Foster AJ
Grondine M
Kantae V
Lamont GM
Lamont S
Lynch JT
Nilsson Lill S
Robb GR
Saeh J
Schimpl M
Scott JS
Smith J
Srinivasan B
Tentarelli S
Vazquez-Chantada M
Wagner D
Walsh JJ
Watson D
Williamson B
Source :
Journal of medicinal chemistry [J Med Chem] 2024 Mar 28; Vol. 67 (6), pp. 4541-4559. Date of Electronic Publication: 2024 Mar 11.
Publication Year :
2024

Abstract

The optimization of an allosteric fragment, discovered by differential scanning fluorimetry, to an in vivo MAT2a tool inhibitor is discussed. The structure-based drug discovery approach, aided by relative binding free energy calculations, resulted in AZ'9567 ( 21 ), a potent inhibitor in vitro with excellent preclinical pharmacokinetic properties. This tool showed a selective antiproliferative effect on methylthioadenosine phosphorylase (MTAP) KO cells, both in vitro and in vivo, providing further evidence to support the utility of MAT2a inhibitors as potential anticancer therapies for MTAP-deficient tumors.

Details

Language :
English
ISSN :
1520-4804
Volume :
67
Issue :
6
Database :
MEDLINE
Journal :
Journal of medicinal chemistry
Publication Type :
Academic Journal
Accession number :
38466661
Full Text :
https://doi.org/10.1021/acs.jmedchem.3c01860